Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claims Status
The amendments filed 07/13/2026 are acknowledged.
Claims 1-21 are pending.
Claims 1-7 and 17-21 are amended.
Election/Restrictions
Applicant’s election with traverse of Group I, claims 1-7, in the reply filed on 07/13/2026 is acknowledged. The traversal is on the grounds that the claims are linked through the specifically defined anti-Nectin-4 antibody having the recited sequences and the ADC, and that the antibody, the nucleic acid, and the expression materials used to produce the antibody, ADC, compositions containing the ADC, and methods employing the ADC are technically interrelated parts, and that the claimed inventions share a technical relationship involving the antibody and ADC features that define the disclosed contribution over the prior art. This is not found persuasive because the special technical feature of the specifically defined anti-Nectin-4 antibody having the recited sequences and the ADC is not a special technical feature as it is taught in the prior art, which is demonstrated in the rejections below. Further, as stated in the restriction requirement, Group II (claims 8-11) does not require the antibody-drug conjugate targeting Nectin-4 or salt thereof of Group I, the anti-nectin-4 antibody of Group III, or the nucleic acid molecule of Group IV, Group III (claims 14-17) does not require the antibody-drug conjugate targeting Nectin-4 or salt thereof of Group I or the nucleic acid molecule of Group IV, Groups I-III do not require the nucleic acid molecule of Group IV, Group V does not require the anti-Nectin-4 antibody of Group III. Further, there is no similar structure or function between a protein and a nucleic acid. Thus, the Groups do not share a technical relationship and additionally, Group III is the second claimed product, Group IV is the third claimed product, and Group V is the second claimed method, and therefore, these do not fall under one of the permitted categories.
The Examiner notes that claim 18 has been amended to require the ADC of claim 1. However, the claim is directed to a “use of” the ADC which is not a proper claim format. See MPEP 2173.05(q). The “use of” implies a method, which is being held as non-elected.
Applicant’s election with traverse of the following species is acknowledged: SEQ ID NOs: 19, 20, 13 and 14, 15, 16 for the sequences of the CDR-H1-3 and CDR-L1-3, respectively, SEQ ID NO: 5 for the VH, SEQ ID NO: 6 for the VL, Formula Ib, ADC-3, C-3 for the drug-linker, and bladder cancer. The traversal is only regarding the listed cancer species (i.e. Species Group G) and is on the grounds that the action does not identify a different in the claimed ADC mechanism for treating one listed cancer rather than another. This is not found persuasive because this is not the standard for an election of species. The Examiner clearly stated that the different cancers and/or tumors have different modes of operation, effects, and/or etiologies, and therefore, these do not share the same or corresponding technical feature.
The requirement is still deemed proper and is therefore made FINAL. Therefore, claims 8-21 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention and/or species there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 07/13/2026.
Therefore, claims 1-7 are under examination.
Priority
The instant application is a 371 of PCT/CN2022/090450 and claims priority to Chinese application CN202110481199.4. Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Priority is given with the earliest effective filing date of 04/30/2021.
Information Disclosure Statement
The information disclosure statement (IDS) submitted on 12/14/2023 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.
Claim Rejections - 35 USC § 112(b)
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 2-7 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claims 2-7 include the limitation(s) “preferably” and/or “more preferably”, claims 4-6 include the limitation “e.g.”, and claim 5 includes the limitation “in particular”. MPEP 2173.05(d) states, “Description of examples or preferences is properly set forth in the specification rather than the claims. If stated in the claims, examples and preferences may lead to confusion over the intended scope of a claim.” The “preferably”, “more preferably”, “e.g.”, and “in particular” make it unclear if the limitations that succeed these terms are required claim limitations or simply preferred/exemplary. Therefore, the scope of these claims is indefinite.
Claim 4 recites the limitation “wherein the anti-Nectin-4 antibody or fragment thereof is in any form”. It is unclear what is meant by “any form”. The claim lists exemplary language following the “any form”, however, antibody forms in the art generally refers to the different antibody isotypes (i.e. IgG, IgA, IgM, IgE, and IgD) [see Mandal, 2023; instant PTO-892]. Claim 4 also recites “or a chimeric antibody and the like.” It is unclear what the metes and bounds of “and the like” are. Therefore, the scope of this claim is indefinite.
Claim 4 further recites the limitation “a nanobody”. “Nanobody” is trademarked. While not per se indefinite, the term must be analyzed to determine how the mark or name is used in the claim. Here, the trademark is used as a claim limitation to describe a particular material and thus the claim scope is uncertain since the mark or name cannot be used to properly identify any particular material or product but rather only identifies the source of the material. See MPEP 2173.05(U). The compounds should be claimed using the generic term (i.e. a single domain antibody).
Claim Rejections - 35 USC § 112(d)
The following is a quotation of 35 U.S.C. 112(d):
(d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph:
Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
Claim 4 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 4 recites the limitation “wherein the anti-Nectin-4 antibody or fragment is in any form, e.g.,… a single domain antibody or a nanobody..”. A single domain antibody, also known as a nanobody, only comprises a single heavy chain variable domain. Therefore, this would not comprise all the limitations of instant claim 1 (i.e. the VH and VL CDRs 1-3), from which claim 4 depends. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements.
Claim Interpretation
Claims 2-7 recite the limitations “preferably” and/or “more preferably” and claim 5 recites “in particular”. The Examiner is interpreting everything that succeeds the “preferably”, “more preferably”, and/or “in particular” as optional and not required claim limitations, and as such, these limitations are not necessarily included in the rejections below.
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
Claims 1, 4 and 5 are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Ren; WO2021213434 (instant PTO-892).
Regarding claim 1, Ren teaches an antibody against Nectin-4 (i.e. anti-Nectin-4) [0003] and teaches that the heavy chain variable region can comprise SEQ ID NO: 21 and the heavy chain variable region can comprise SEQ ID NO: 25 [0033, 0260-0261]. Ren further teaches an antibody drug conjugate comprising the antibody of the instant invention [0067].
SEQ ID NO: 21 of Ren comprises CDRs with 100% sequence identity to SEQ ID NOs: 19, 20, and 13, respectively, of instant claim 1, and SEQ ID NO: 25 of Ren comprises CDRs with 100% sequence identity to SEQ ID NOs: 14, 15, and 16, respectively, of instant claim 1.
Regarding claims 4 and 5, Ren teaches that the anti-Nectin-4 is a monoclonal antibody or a single-chain antibody [0055].
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
Claims 1-2 and 4-5 are rejected under 35 U.S.C. 103 as being unpatentable over Ren; WO2021213434 (instant PTO-892), as applied to claims 1, 4, and 5 above, and further in view of McCombs et al., 2015 (instant PTO-892).
The teachings of Ren are above.
However, Ren does not specifically teach that the ADC has a formula of Ab-[L-CTD]m.
Regarding claim 2, McCombs teaches that the main components of ADCs are the antibody, the linker, and the payload [see Abstract] and that while many drugs are amendable to direct conjugation to an antibody scaffold, linkers often facilitate ADC bioconjugation [page 344, left column, second paragraph]. McCombs further teaches that a majority of ADCs are built on IgG1 scaffolds and that the IgG scaffold has over 20 lysine residues that lead to a wide range of possible drug to antibody ratios at varying conjugation sites [page 339, right column, second-fourth paragraphs] (i.e. Ab-[L-CTD]m).
It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have specifically structured the ADC of Ren to have the formula of Ab-[L-CTD]m as taught by McCombs. One would have been motivated to have structured the ADC of Ren to have the formula of Ab-[L-CTD]m because McCombs teaches that the main components of ADCs are the antibody, the linker, and the payload and this is the standard structure for ADCs. There would be a reasonable expectation of success in structuring the ADC of Ren to have the formula of Ab-[L-CTD]m because this is a known parameter in the art, as taught by McCombs.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Copending Application No. 19/124,804 (‘804)
Claims 1-3 and 6-7 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-5 of copending Application No. 19/124,804 (‘804) (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other.
Regarding claims 1 and 2 of the instant application, claim 1 of the reference application teaches a liquid formulation comprising an anti-Nectin-4 antibody-drug conjugate or salt thereof as well as a buffer and an auxiliary material; characterized in that, the anti-Nectin-4 antibody-drug conjugate or salt thereof has a formula: Ab-[L-CTD]m, in which Ab represents an anti-Nectin-4 antibody or fragment thereof comprising three heavy chain complementarity determining regions, i.e., H-CDR1, H-CDR2, and H-CDR3, and three light chain complementarity determining regions, i.e., L-CDR1, L-CDR2, and L-CDR3, wherein the H-CDR1 comprises the amino acid sequence (DYGVS) shown in SEQ ID NO. 3, the H-CDR2 comprises the amino acid sequence (VIWGGGKIYYNSVLKS) shown in SEQ ID NO. 4, and the H-CDR3 comprises the amino acid sequence (QGGLLFYAMDY) shown in SEQ ID NO. 5; and, the L-CDR1 comprises the amino acid sequence (KSSQSLLNTYSQKNYLA) shown in SEQ ID NO. 8, the L-CDR2 comprises the amino acid sequence (FASTRES) shown in SEQ ID NO. 9, and the L-CDR3 comprises the amino acid sequence (QQHYNTPFT) shown in SEQ ID NO. 10; L represents a linker; CTD represents a drug; and m represents the average number of drug molecules conjugated to one Ab molecule (average DAR) and claim 2 of the reference application teaches that CTD is a cytotoxic drug; preferably, CTD is one or more selected from the group consisting of: microtubule inhibitors MMAE, DM1, DM4, Tublysin, amanitin, cachimycin, Eribulin and derivatives thereof; topoisomerase inhibitors SN38, Exatecan and derivatives thereof; and DNA binding agents PBD, doxorubicin and derivatives thereof; m is 1.0 to 5.0, preferably 3.0 to 4.2, more preferably 3.5 to 4.5, still more preferably 3.8 to 4.2, yet more preferably 3.9 to 4.1, and particularly preferably 4.0.
SEQ ID NOs: 3, 4, 5 and 8, 9, 10 have 100% sequence identity to SEQ ID NOs: SEQ ID NOs: 19, 20, 13 and 14, 15, 16, respectively, of instant claim 1.
Regarding claim 3 of the instant application, claim 5 of the reference application teaches that the anti-Nectin-4 antibody or fragment thereof comprises a heavy chain variable region (VH) comprising the amino acid sequence shown in SEQ ID NO: 2 or a variant thereof; and, the anti-Nectin-4 antibody or fragment thereof comprises a light chain variable region (VL) comprising the amino acid sequence shown in SEQ ID NO: 7 or a variant thereof; preferably, the anti-Nectin-4 antibody or fragment thereof comprises a heavy chain (HC) comprising the amino acid sequence shown in SEQ ID NO: 1 or a variant thereof; and the anti-Nectin-4 antibody or fragment thereof comprises a light chain (LC) comprising the amino acid sequence shown in SEQ ID NO: 6 or a variant thereof.
SEQ ID NOs: 2 and 7 have 100% sequence identity to SEQ ID NOs: 5 and 6 of the instant claim, respectively.
Regarding claim 6 of the instant application, claim 3 of the reference application teaches that the anti-Nectin-4 antibody-drug conjugate or salt thereof has a structure represented by the formula I as follows:
PNG
media_image1.png
158
284
media_image1.png
Greyscale
in which: Ab is the anti-Nectin-4 antibody or fragment thereof;
Ar' is any one selected from the group consisting of: substituted or unsubstituted C6-C 10 arylene and substituted or unsubstituted 5-12 membered heteroarylene, wherein the
substitution refers to the replacement of a hydrogen atom on a group by one or more
substituents selected from the group consisting of: halogen (F, Cl, Br or I), halogenated alkyl (e.g. halogenated C1-C6 alkyl, preferably halogenated C1-C4 alkyl, e.g. trifluoromethyl) and alkoxy (e.g. C1-C6 alkoxy, preferably C1-C4 alkoxy, e.g. methoxy);
L1 is -O(CH2CH2O)n- linked to Ar', in which n is any integer in the range from 1 to 24, preferably from 1 to 10, more preferably from 3 to 5; L2 is an enzyme cleavable fragment, which is selected from the group consisting of a dipeptide or a tripeptide or a tetrapeptide or a combination of the dipeptide or the tripeptide or the tetrapeptide with a self-immolative linker, such as Val-Ala, Val-Ala-PAB, Val-Cit, Val-Cit-PAB, Phe-Lys-PAB, Ala-Ala-Ala, Gly-Gly-Phe-Gly (GGFG), MAC glucuronide phenol; preferably, L2-CTD is VcMMAE, GGFG-Dxd or VC-seco-DUBA; preferably, in the case that Ar' is a substituted or unsubstituted 5-12 membered heteroarylene, the heteroatom is N; preferably, Ar' is a substituted or unsubstituted C6 arylene or a substituted or unsubstituted 6 membered heteroarylene.
Regarding claim 7 of the instant application, claim 4 of the reference application teaches that the anti-Nectin-4 antibody-drug conjugate or salt thereof has a structure as follows:
PNG
media_image2.png
274
732
media_image2.png
Greyscale
This structure is identical to the structure of Conjugate ADC-3 (as elected).
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Claims 1-7 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-5 of copending Application No. 19/124,804 (‘804) (reference application), as applied to claims 1-3 and 6-7 above, in view of Thomas et al., 2019 (instant PTO-892).
The teachings of the reference application are above.
However, the reference application does not specifically teach that the antibody is a monoclonal antibody.
Regarding claims 4-5 of the instant application, Thomas teaches that antibody-drug conjugates are monoclonal antibodies conjugated to cytotoxic agents [see Abstract].
It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have specifically structured the ADC of the reference application to comprise a monoclonal antibody as taught by Thomas. One would have been motivated to have structured the ADC of the reference application to comprise a monoclonal antibody because Thomas teaches that antibody-drug conjugates are monoclonal antibodies conjugated to cytotoxic agents. There would be a reasonable expectation of success in structuring the ADC of the reference application to comprise a monoclonal antibody because this is a known parameter in the art, as taught by Thomas.
This is a provisional nonstatutory double patenting rejection.
Copending Application No. 19/503,994 (‘994)
Claims 1-4 and 6-7 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 4-5, 8, 14, and 15 of copending Application No. 19/503,994 (‘994) (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other.
Regarding claim 1 of the instant application, claim 1 of the reference application teaches a pharmaceutical combination comprising (i) an anti-Nectin4 antibody-drug conjugate or a pharmaceutically acceptable salt thereof, wherein the anti-Nectin4 antibody-drug conjugate or the pharmaceutically acceptable salt thereof has a molecular formula of Ab-[L-CTD]m, wherein Ab represents an anti-Nectin-4 antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1 shown in SEQ ID NO: 1, HCDR2 shown in SEQ ID NO:2, and HCDR3 shown in SEQ ID NO:3; and the light chain variable region comprises LCDR1 shown in SEQ ID NO:4, LCDR2 shown in SEQ ID NO:5, and LCDR3 shown in SEQ ID NO:6; L represents a linker, CTD represents a drug, and m represents an average number of drugs conjugated per Ab molecule; and (ii) an anti-PD-1 antibody or an antigen-binding fragment thereof.
SEQ ID NOs: 1, 2, 3 and 4, 5, 6 have 100% sequence identity to SEQ ID NOs: SEQ ID NOs: 19, 20, 13 and 14, 15, 16, respectively, of the instant claim.
Regarding claim 2 of the instant application, claim 4 of the reference application teaches the anti-Nectin4 antibody-drug conjugate or the pharmaceutically acceptable salt thereof has a molecular formula of Ab-[L-CTD]m, wherein CTD is a cytotoxic drug; optionally CTD is one or more selected from the group consisting of: microtubule inhibitors MMAE, DMl, DM4, Tublysin, amanitin, calicheamicin, Eribulin and derivatives thereof; topoisomerase inhibitors SN38, Exatecan and derivatives thereof; and DNA binding agents PBD, doxorubicin and derivatives thereof; optionally, m is 1.0 to 5.0, or 3.0 to 4.2, or 3.5 to 4.5, or 3.8 to 4.2, or 3.9 to 4.1, or 4.0.
Regarding claim 3 of the instant application, claim 5 of the reference application teaches the anti-Nectin4 antibody-drug conjugate or the pharmaceutically acceptable salt thereof has a molecular formula of Ab-[L-CTD]m, wherein Ab represents an anti-Nectin-4 antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence shown in SEQ ID NO: 7 or SEQ ID NO: 9, and the light chain variable region comprises an amino acid sequence shown in SEQ ID NO: 8 or SEQ ID NO: 10; optionally, the Ab comprises (i) a heavy chain variable region amino acid sequence shown in SEQ ID NO: 7; and a light chain variable region amino acid sequence shown in SEQ ID NO: 8.
SEQ ID NOs: 7 and 8 of the reference application have 100% sequence identity to SEQ ID NOs: 5 and 6 of the instant claim, respectively.
Regarding claim 4 of the instant application, claim 8 of the reference application teaches that the antibody is an IgG antibody, optionally a human IgG antibody, optionally a human IgG1 or human IgG4 antibody; and wherein the antigen-binding fragment is Fab, Fab', F(ab')2, Fv, single-chain Fv, or single-chain Fab.
Regarding claim 6 of the instant application, claim 14 of the reference application teaches that the anti-Nectin4 antibody-drug conjugate or the pharmaceutically acceptable salt thereof has a structure shown in Formula Ia and/or lb below:
PNG
media_image3.png
154
610
media_image3.png
Greyscale
Wherein: Ab is the anti-Nectin-4 antibody or antigen-binding fragment thereof;
Ar' is any one selected from the group consisting of: substituted or unsubstituted C6-C 10 arylene and substituted or unsubstituted 5-12 membered heteroarylene, wherein the substitution refers to the replacement of a hydrogen atom on a group by one or more substituents selected from the group consisting of: halogen (F, Cl, Br or I), halogenated alkyl (or halogenated Cl-C6 alkyl, optionally halogenated Cl-C4 alkyl, or trifluoromethyl) and alkoxy (or Cl-C6 alkoxy, optionally C l-C4 alkoxy, or methoxy);
L1 is -O(CH2CH2O)n- linked to Ar', wherein n is any integer selected from the group consisting of 1 to 24, or any integer from 1 to 10, or any integer from 3 to 5;
L2 is an enzyme cleavable fragment, or, a dipeptide or a tripeptide or a tetrapeptide or a combination thereof with a self-immolating structural fragment (which is a polypeptide fragment consisting of 2-4 amino acids, or a combination of the polypeptide fragment with a self-immolating structural fragment), or Val-Ala, Val-Ala-PAB, Val-Cit, Val-Cit-PAB, Phe-Lys-PAB, Ala-Ala-Ala, Gly-Gly-Phe-Gly (GGFG), MAC glucuronide phenol.
Regarding claim 7 of the instant application, claim 15 of the reference application teaches that the L2-CTD is VcMMAE, GGFG-Dxd, or VC-seco-DUBA; optionally, if Ar' is a substituted or unsubstituted 5-12 membered heteroarylene, then the heteroatom is N; optionally, Ar' is a substituted or unsubstituted C6 arylene, or a substituted or unsubstituted 6 membered heteroarylene; optionally, the antibody drug conjugate or the pharmaceutically acceptable salt thereof has the following structure:
PNG
media_image4.png
218
680
media_image4.png
Greyscale
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Claims 1-7 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 4-5, 8, 14, and 15 of copending Application No. 19/503,994 (‘994) (reference application), as applied to claims 1-4 and 6-7 above, in view of Thomas et al., 2019 (instant PTO-892).
The teachings of the reference application are above.
However, the reference application does not specifically teach that the antibody is a monoclonal antibody.
Regarding claim 5 of the instant application, Thomas teaches that antibody-drug conjugates are monoclonal antibodies conjugated to cytotoxic agents [see Abstract].
It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have specifically structured the ADC of the reference application to comprise a monoclonal antibody as taught by Thomas. One would have been motivated to have structured the ADC of the reference application to comprise a monoclonal antibody because Thomas teaches that antibody-drug conjugates are monoclonal antibodies conjugated to cytotoxic agents. There would be a reasonable expectation of success in structuring the ADC of the reference application to comprise a monoclonal antibody because this is a known parameter in the art, as taught by Thomas.
This is a provisional nonstatutory double patenting rejection.
Conclusion
No claims are allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brittney E Donoghue whose telephone number is (571)272-9883. The examiner can normally be reached Mon - Fri 7:30 - 3:30.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Stucker can be reached at (571) 272-0911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/B.E.D./Examiner, Art Unit 1675
/JEFFREY STUCKER/Supervisory Patent Examiner, Art Unit 1675